AU Patent

AU2009201650B2 — Formulations of suberoylanilide hydroxamic acid and methods for producing same

Assigned to Merck Sharp and Dohme LLC · Expires 2011-09-15 · 15y expired

What this patent protects

Formulations of Suberoylanilide Hydroxamic Acid and Methods for Producing Same Abstract 100.0 - 5__1 U-I-_ 0 10 20 so 4Q so so 70 Tc., irirtcs The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which compris…

USPTO Abstract

Formulations of Suberoylanilide Hydroxamic Acid and Methods for Producing Same Abstract 100.0 - 5__1 U-I-_ 0 10 20 so 4Q so so 70 Tc., irirtcs The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline to composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.

Drugs covered by this patent

Patent Metadata

Patent number
AU2009201650B2
Jurisdiction
AU
Classification
—
Expires
2011-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.